Newsroom | 9027 results

HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Saptalis Pharmaceuticals, LLC. is pleased to announce the commercial launch of Fluoxetine Oral Solution, USP 20 mg/5 mL, a prescription-only selective serotonin reuptake inhibitor (SSRI) developed to treat a range of mental health conditions effectively. This oral formulation is designed to support flexible and individualized treatment, particularly for patients who experience difficulty swallowing solid dosage forms. Fluoxetine Oral Solution is indicated for t...

COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a digital health leader revolutionizing AI-driven cardiometabolic care, today announced its selection by Modern Healthcare as one of the 2025 Best Places to Work in Healthcare. This national award recognizes top employers in the healthcare industry. The highly competitive selection process, conducted in partnership with Workforce Research Group, involved an extensive employee survey. Welldoc was named to the list alongside a select group of health tech...

BRENTWOOD, Tenn.--(BUSINESS WIRE)--Tractor Supply Company (NASDAQ: TSCO), the largest rural lifestyle retailer in the United States, and the Tractor Supply Company Foundation announced today they are donating an additional $1 million in total to charity organizations committed to supporting our nation’s military service members, veterans and first responders. The Company and its foundation made an initial $1 million donation in June 2024 to celebrate the launch of its Hometown Heroes initiative...

AUSTIN, Texas--(BUSINESS WIRE)--BetterUp®, the human transformation company, today announces the renewal of its partnership with the Invictus Games Foundation, reaffirming its commitment to supporting the mental fitness and recovery of the global Invictus Community which is comprised of veterans and service personnel living with life-altering injuries or illnesses. As an Official Partner of the Invictus Games Foundation, BetterUp will continue to offer no cost access to its proprietary human tr...

LONDON--(BUSINESS WIRE)--New research from Medscape UK into doctors’ mental and physical well-being, and their lives outside work, highlights concerns around doctors' welfare....

スペイン、バルセロナ--(BUSINESS WIRE)--（ビジネスワイヤ） -- Bコープ認証を受けている国際的製薬会社のフェレールは、アセニューロンからライセンス導入し、進行性核上性まひ（PSP）の発症を遅らせることを目的として開発している新しい治療薬FNP-223が、米国食品医薬品局（FDA）からファストトラック指定を受けたと発表しました。FNP-223は、神経変性疾患であるPSPの治療薬候補の新しい分子化合物であり、現在、PSPの最も一般的な臨床型であるPSP-リチャードソン症候群（PSP-RS）が疑われる、または診断された成人患者を対象に、FNP-223の安全性、有効性、薬物動態を評価する第2相臨床試験が行われています。1 「FDAからPSP治療におけるFNP-223のファストトラック指定を受け、大変嬉しく思っています。ビジネスを通じて社会正義のために闘うという当社の目的に沿って、私たちはこの有望な治療法を可及的速やかに（上市まで）前進させ、一人でも多くの患者さんに恩恵をもたらせるよう専念しています」と、フェレールのマリオ・ロビロサ最高経営責任者（CEO）は述べました。 フ...

西班牙巴塞罗那--(BUSINESS WIRE)--(美国商业资讯)-- 获得共益企业认证的国际制药公司Ferrer宣布，其从Asceneuron引进的新型疗法FNP-223已获得美国食品药品管理局(FDA)的快速通道认定。该药物旨在延缓进行性核上性麻痹(PSP)的发展。FNP-223是一种正在开发的用于PSP的新分子实体，目前正在进行2期研究，以评估其在可能或很可能患有PSP-理查森综合征(PSP-RS)的成年患者中的安全性、有效性和药代动力学。PSP-RS是这种神经退行性疾病最常见的临床变异型1。 Ferrer首席执行官Mario Rovirosa表示：“我们很高兴FNP-223治疗PSP获得FDA快速通道认定。秉承‘以商业力量推动社会正义’的宗旨，我们致力于尽快推进这一有前景的疗法，让尽可能多的患者受益。” 快速通道认定是药物开发过程中的重要里程碑。该计划允许与FDA更频繁地召开会议，以讨论药物开发进程，若满足相关标准，还可获得加速批准和优先审评资格。 Ferrer首席质量、法规和药物警戒官Marta Parmar表示：“这一认定凸显了加速FNP-223开发和审评的重要性，以解决...

BARCELONA, Espanha--(BUSINESS WIRE)--A Ferrer, uma empresa farmacêutica internacional certificada pela B Corp, anunciou que a FNP-223, uma nova terapia licenciada pela Asceneuron e destinada a retardar o desenvolvimento da paralisia supranuclear progressiva (PSP), recebeu a designação Fast Track da Food & Drug Administration (FDA) dos EUA. A FNP-223, uma nova entidade molecular em desenvolvimento ativo para PSP, está em um estudo de fase 2 em curso para avaliar sua segurança, eficácia e far...

BARCELONA, Spanje--(BUSINESS WIRE)--Ferrer, een internationaal B Corp-gecertificeerd farmaceutisch bedrijf, maakt bekend dat FNP-223, een nieuwe therapie onder licentie van Asceneuron bedoeld om de ontwikkeling van PSP (Progressieve Supranucleaire Parese) te vertragen, van de Amerikaanse FDA (US Food & Drug Administration) een Fast Track-aanduiding heeft ontvangen. FNP-223, een nieuwe moleculaire entiteit in actieve ontwikkeling voor PSP, is in een lopende Fase 2-studie om de veiligheid, de...

BARCELONE, Espagne--(BUSINESS WIRE)--Ferrer, entreprise pharmaceutique internationale certifiée B Corp, a annoncé que le FNP-223 – un nouveau traitement sous licence d’Asceneuron visant à ralentir la progression de la paralysie supranucléaire progressive (PSP) – a reçu la désignation « Fast Track » (procédure accélérée de développement et d’évaluation) de la Food and Drug Administration (FDA) des États-Unis. Le FNP-223, une nouvelle entité moléculaire développée pour le traitement de la PSP, fa...